|1.||Camilleri, M: 3 articles (02/2007 - 09/2001)|
|2.||Dibble, Suzanne L: 3 articles (07/2005 - 03/2003)|
|3.||Luce, Judith: 3 articles (07/2005 - 03/2003)|
|4.||Dehpour, Ahmad Reza: 2 articles (12/2015 - 09/2014)|
|5.||Zirak, Mohammad Reza: 2 articles (12/2015 - 09/2014)|
|6.||Rahimian, Reza: 2 articles (12/2015 - 09/2014)|
|7.||Mousavizadeh, Kazem: 2 articles (12/2015 - 09/2014)|
|8.||Chey, William D: 2 articles (04/2015 - 07/2009)|
|9.||Gan, Tong J: 2 articles (05/2006 - 01/2005)|
|10.||Roila, Fausto: 2 articles (02/2005 - 01/2003)|
01/01/2002 - "The ipecacuanha model of emesis has been used to test the anti-emetic activity of several different 5-HT3 antagonists and the anti-emetic doses that were effective in the ipecacuanha model have been found to correlate well with the clinically effective doses. "
01/01/2004 - "In conclusion, the study showed that almost all patients received prophylaxis for acute emesis and that there is overprescription of 5-HT3 antagonists. "
01/01/2006 - "All patients received at least one 5-HT3 antagonist for emesis prophylaxis. "
07/01/2002 - "Clinically, 5-HT3 antagonists are important in the treatment of emesis and have been used for the treatment of symptoms in functional bowel disease. "
04/01/2000 - "The effect of 5-HT3 antagonists was judged by both the score for the severity of the emesis and the frequency of vomiting. "
12/01/1989 - "5-HT3 antagonists at high doses are effective in treating nausea and at low doses in treating anxiety. "
02/01/2002 - "The 5-HT3 antagonist reduced postprandial symptoms (aggregate score: P < 0.05), nausea (P < 0.001), and tended to reduce bloating (P=0.08). "
09/01/2000 - "The introduction of serotonin 5-HT3 receptor antagonists into clinical practice allowed for a dramatic improvement in the management of nausea and vomiting. "
10/01/2003 - "5-HT3 antagonists are a comparatively new class of drugs that seem to perform satisfactory in the treatment of different forms of nausea and vomiting with few adverse reactions. "
05/01/1996 - "The results of this pilot study showed the excellent effect of the new 5-HT3 antagonist, ondansteron, in prevention of radiation-induced nausea and emesis. "
|3.||Postoperative Nausea and Vomiting (PONV)
01/01/2006 - "This article explains the clinical pharmacology of 5-HT3 antagonists and provides recommendations for nursing management of PONV."
01/01/2005 - "Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?"
01/01/1992 - "5-HT3 antagonists in postoperative nausea and vomiting."
01/01/2000 - "The 5-HT3 antagonists are effective in reducing postoperative nausea and vomiting (PONV) associated with paediatric tonsillectomy. "
08/01/1998 - "RS-25259, a long-acting 5-HT3 antagonist, was effective in reducing postoperative vomiting only at the largest dose studied (30 microg/kg). "
|4.||Alcoholism (Alcohol Abuse)
08/01/1994 - "Ondansetron was very well tolerated; hence, further long-term studies with 5-HT3 antagonists alone or in combination with other treatment components may offer promise for treatment of alcoholism."
09/01/1994 - "Overall, these results do not support the hypothesis that the serotonin 5-HT3 antagonists would have robust therapeutic efficacy in the treatment of alcoholism."
01/01/2000 - "By attenuating the rewarding effects of ethanol or of ethanol conditioned cues (e.g., the operant environment), 5-HT3 antagonists may be useful in the treatment of alcohol abuse. "
08/01/1994 - "Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence."
01/01/2004 - "Ondansetron, a 5-HT3 antagonist, is an efficacious and promising medication for the treatment of early-onset alcoholism. "
04/01/2014 - "Despite the advent of 5-HT3 antagonists, control of delayed gastrointestinal adverse events with cancer chemotherapy is still not optimal. "
08/01/1990 - "5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment."
04/01/2000 - "[Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers]."
07/01/1998 - "The 5-HT3 antagonists, used either alone or in combination with a corticosteroid, have almost completely supplanted all other types of antiemetic regimens for preventing cancer chemotherapy-induced emesis. "
01/01/2001 - "The study allowed an effective 5-HT3 antagonist protocol to be developed for use in the management of nausea and vomiting in cancer patients."
|7.||Serotonin (5 Hydroxytryptamine)
|10.||Serotonin 5-HT4 Receptor Agonists
|1.||Drug Therapy (Chemotherapy)
|5.||Hematopoietic Stem Cell Transplantation